John Schiel played a leading role in the development of a protein therapeutic measurements and standards program that works closely with the biopharmaceutical industry, regulators, and instrumentation companies. Specifically, he led a team of NIST scientists in developing a world-first monoclonal antibody reference material, NISTmAb, a global benchmark that assures the performance of biopharmaceutical drug product release tests and new analytical tools and supports the development of manufacturing technologies.